Financial Comparison: Elixinol Wellness (OTCMKTS:ELLXF) versus Intensity Therapeutics (NASDAQ:INTS)

Intensity Therapeutics (NASDAQ:INTS) and Elixinol Wellness (OTCMKTS:ELLXF) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Valuation & Earnings

This table compares Intensity Therapeutics and Elixinol Wellness”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61 million	($5.71)	-0.69
Elixinol Wellness	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for Intensity Therapeutics and Elixinol Wellness, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1	0	2	1	2.75
Elixinol Wellness	0	0	0	0	0.00

Intensity Therapeutics presently has a consensus price target of $37.50, suggesting a potential upside of 846.97%. Given Intensity Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Intensity Therapeutics is more favorable than Elixinol Wellness.

Insider and Institutional Ownership

3.7% of Intensity Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Intensity Therapeutics and Elixinol Wellness’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Elixinol Wellness	N/A	N/A	N/A

Summary

Intensity Therapeutics beats Elixinol Wellness on 6 of the 8 factors compared between the two stocks.

About Intensity Therapeutics

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

About Elixinol Wellness

Elixinol Wellness Limited, through its subsidiaries, engages in the manufacture and distribution of hemp derived nutraceuticals, skincare, and food products in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.